In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.
What were the key events shaping the global pharmaceutical industry in 2014? DCAT Value Chain Insights (VCI) reviews the highlights from 2014.
The end of the year is typically a time of reflection, and in looking back at 2014, what were the key...
Sun Pharmaceutical Industries Ltd has moved closer to finalizing its acquisition of Ranbaxy Laboratories. The company have received approval from the Competition Commission of India, subject to certain product divestments and other terms. DCAT...
Merck & Co. has agreed to acquire Cubist Pharmaceuticals, a biopharmaceutical company specializing in antibiotics, particularly for multidrug-resistant bacteria, for $9.5 billion. DCAT Value Chain Insights (VCI) examines the proposed...
Diabetes spending growth is projected to exceed 10% in both developed and emerging markets over the next five years, driven by innovative new therapies and greater diagnosis rates.
The diabetes market is projected to see a major influx of new...
Specialty medicines are an important engine of growth for the global pharmaceutical market, projected to account for 40% of the market by 2018. So what are the leading therapeutic classes and key drugs in these classes? DCAT Value Chain Insights...
A recent study by the Tufts Center for the Study of Drug Development estimates the cost of developing a new drug at nearly $2.6 billion.
So what is the cost for new drug development? A recent study by the Tufts Center for the Study of Drug...
More specialty drug innovation, greater patient access to medicines, and reduced impact from patent expiries will be the primary drivers behind increase in global medicine spending through 2018.
The global pharmaceutical market is showing signs of...
Reckitt Benckiser has announced plans to spin off its pharmaceutical business with its shareholders voting on the plan at a meeting scheduled for December 11, 2014. If approved, the newly formed company, Indivior, will create a specialty...
The Lilly MDR-TB Partnership, a public-private partnership set up by Eli Lilly to address the problem of multidrug-resistant tuberculosis (MDR-TB), is a successful example of a global health initiative involving technology transfer and...
The decision last week by Sanofi's board of directors to remove Sanofi CEO Christopher A. Viehbacher spells a major change for the company. As interim CEO Serge Weinberg takes the helm of the company, DCAT Value Chain Insights (VCI) takes an inside...
